Zymergen (NASDAQ:ZY – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Zymergen to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Insider and Institutional Ownership
48.8% of Zymergen shares are owned by institutional investors. Comparatively, 56.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 10.6% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Zymergen and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Zymergen | $16.74 million | -$361.79 million | -0.19 |
| Zymergen Competitors | $2.79 billion | $101.13 million | 22.12 |
Zymergen’s competitors have higher revenue and earnings than Zymergen. Zymergen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Zymergen and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zymergen | 3 | 5 | 0 | 0 | 1.63 |
| Zymergen Competitors | 100 | 745 | 1293 | 30 | 2.58 |
Zymergen presently has a consensus target price of $6.75, suggesting a potential upside of 275.00%. As a group, “Commercial physical research” companies have a potential upside of 27.51%. Given Zymergen’s higher possible upside, equities research analysts clearly believe Zymergen is more favorable than its competitors.
Profitability
This table compares Zymergen and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zymergen | -2,160.81% | -213.99% | -64.50% |
| Zymergen Competitors | -255.16% | -16.00% | -2.18% |
Summary
Zymergen competitors beat Zymergen on 11 of the 12 factors compared.
Zymergen Company Profile (Get Rating)
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.
Want More Great Investing Ideas?
Receive News & Ratings for Zymergen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zymergen and related companies with MarketBeat.com’s FREE daily email newsletter.
